Atorvastatin-tabletter (10 mg/20 mg) Azithromycin-tabletter (250 mg) Benzafibrat-tabletter (200 mg) Benazepril Hydrochlorid-tabletter Betamethason-tabletter (0,50 mg) BIRB 796-tabletter (100 mg). Cilazapril-tabletter (2,5 mg) Cimetidin-tabletter (200 mg) Ciprofloxacin-tabletter (500 mg) Ciprofloxacin-tabletter (750 mg) Cisaprid-tabletter (5 mg).
INTRODUCTION
HYDROXYPROPYL METHYLCELLULOSE (METHOCEL, HPMC) AQUEOUS COATINGS
C HERRY R ED Bill of Materials
G LOSS
C LEAR
G REEN
The coating solution formulation is formulated to achieve a mass gain of 10 mg per capsule (approximately 600 mg weight), taking into account evaporation and loss during the coating process.
O PADRY G REEN
HYDROXYPROPYL METHYLCELLULOSE OPAQUE ORGANIC COATING
After mixing for 10 minutes, tap off approximately 10 ml from the mixing tank and place back into the tank to recirculate. After 1/2, 1, and 1 1/2 hours, tap approximately 10 mL of solution from the mixing tank and place back into the mixing tank to recirculate.
D ARK R ED
HYDROXYPROPYL
While stirring the alcohol, add and disperse the hydroxypropyl methylcellulose, hydroxypropyl cellulose, and propylene glycol, followed by 250 mL of methylene chloride. While mixing the solution from step two, empty the contents of the bead jar into it, rinse the beads and jar with methylene chloride, and add the rinse to the batch and mix.
HYDROXYPROPYL
PROCESSING DIRECTIONS Place the titanium dioxide and enough methylene chloride in an appropriately sized ball jar to cover the balls.
HYDROXYMETHYL CELLULOSE AND HYDROXY CELLULOSE COATING
C LEAR (50:50) Bill of Materials
HYDROXYMETHYL CELLULOSE AND ETHYL CELLULOSE COATING
Load the hydroxypropylmethylcellulose and the ethylcellulose into the mixing tank. about 500 ml) to bring the final volume to 1 l. The rubber stopper on the bottles must be protected against methylene chloride with a polyethylene layer.
POLYVINYLPYRROLIDONE COATINGS A. S UBCOATING
Turn mixer on to mixing speed; maintain the mixing speed during the preparation of the coating solution.
K OLLIDON VA 64
MANUFACTURING DIRECTIONS Dissolve shellac and sorbitan oleate in the hot solvent, then dissolve Kollidon and cetyl alcohol. Suspend the pigments and talc in the portion of water and pass this mixture through a colloid mill.
Povidone, Ethylcellulose, and Talc
CELLULOSE ACETATE PHTHALATE AND CARBOWAX COATINGS
C HERRY R ED
C LEAR
SUGAR COATINGS A. B ASIC
MANUFACTURING INSTRUCTIONS Dissolve sucrose in hot water, mix with glycerol, dissolve Kollidon 30 and suspend other components. MANUFACTURING INSTRUCTIONS Dissolve Kollidon, polysorbate or Cremophor and sucrose in water and suspend the other components in this solution.
ENTERIC COATINGS
E UDRAGIT E NTERIC A QUEOUS 1. Brick Red
Yellow
Brown
Dark Orange Bill of Materials
Orange
Dispersed Orange
Clear Enteric Bill of Materials
Orchid Pink Opaque
Light Apricot OrangeBill of Materials
These requirements are specified in Code of Federal Regulations, Title 21, Part 320 (21 CFR Part 320) as they apply to dosage forms intended for oral administration. Manufacturers considering the development of new drug products should pay attention to the changes described in section II.B.
BACKGROUND A. G ENERAL
- INDs/NDAs
- ANDAs
- Postapproval Changes
The performance of the clinical trial dosage form can be optimized, in the context of demonstrating safety and efficacy. When the test product has levels significantly lower than those of the reference product, the regulator's concern becomes therapeutic efficacy.
METHODS TO DOCUMENT BA AND BE As noted in § 320.24, several in vivo and in vitro methods
- General Considerations
- Pilot Study
- Pivotal Bioequivalence Studies
- Study Designs
- Study Population
- Single-Dose/Multiple-Dose Studies
- Bioanalytical Methodology
- Pharmacokinetic Measures of Systemic Exposure
Similarly, population dose or concentration-response relationships observed over a lower range of doses, including doses below recommended therapeutic doses, may be able to demonstrate that reduced levels of the test product compared to the reference product with sufficient efficacy be associated. . For approved ANDAs, the drug product must be compared with the reference list drug after the change.
COMPARISON OF BA MEASURES IN BE STUDIES
Dissolution testing is also used to assess batch-to-batch quality, where the dissolution tests, with defined procedures and acceptance criteria, are used to allow batch release. Dissolution testing is also used to provide process control and quality assurance and determine whether it is beyond.
- General Recommendations
- NDAs: BA and BE Studies
- ANDAs: BE Studies
- Waivers of In Vivo BE Studies (Biowaivers)
- Postapproval Changes
The in vivo BE studies should be accompanied by in vitro dissolution profiles for all strengths of each product. Failure to detect similar dissolution profiles may indicate that an in vivo BE study should be performed.
SPECIAL TOPICS A. F OOD -E FFECT S TUDIES
- Parent Drug vs. Metabolites
- Enantiomers vs. Racemates
- Drug Products with Complex Mixtures as the Active Ingredients
The f2 test should be used to compare profiles of the different strengths of the product. The sample collection should be positioned so that the maximum concentration of drug in the blood (Cmax) and the terminal elimination rate constant (lz) can be accurately estimated.
ABBREVIATED DIRECTIONS
The production of compressed solids is a complex process, involving several steps to make powders compressible yet easily dispersible, with the active ingredient being dissolved when placed at the site of application. As a result, formulations that deliver drugs to the site of action while maintaining an appropriate stability profile are valuable.
BIO VS. PRODUCTION BATCHES It is important that the manufacturer compare the drug
However, a formulation as described in this volume requires an understanding of the manufacturing environment conducive to the manufacture of a compatible dosage form. The sections in this chapter highlight some of these considerations that would benefit formulators.
CLEANING VALIDATION
COATINGS
Evaporation of the solvents leaves a thin film that adheres directly to the tablet and allows it to retain its original shape, including grooves or identification codes. Such coatings are intended to delay the release of the drug until the tablet passes through the stomach.
COMPLIANCE WITH REGULATORY REQUIREMENTS
Film coatings consist of water-soluble or dispersible materials such as hydroxypropylmethylcellulose, methylcellulose, hydroxypropylcellulose, carboxymethylcellulose sodium, and mixtures of cellulose acetate phthalate and polyethylene glycols applied by non-aqueous or aqueous solvents. Where the drug may be destroyed or inactivated by gastric juice, or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated.
COMPRESSION PROCESS CONTROL Compressed solids are subject to dissolution problems. As
CONTENT UNIFORMITY
CROSS-CONTAMINATION
DESEGREGATION OF POWDERS Differences in particle sizes, particle shapes, hydrophilic-
DISINTEGRATION TEST
DISSOLUTION
If water or a medium with a pH lower than 6.8 is specified as the culture medium in the individual monograph, the same specified medium may be used with the addition of purified pepsin resulting in an activity of 750,000 units or less per 1000 ml. For media with a pH of 6.8 or greater, pancreatin may be added to produce a maximum of 1750 USP units of protease activity per 1000 mL.
DISINTEGRATION AND DISSOLUTION Disintegration is an essential attribute of tablets intended
DRUG SUBSTANCE CHARACTERIZATION Characterization of the chemical and physical properties
DRYING PROCESS
DYES IN FORMULATIONS
EQUIPMENT
- Pony Pan
- Ribbon
- Tumbler
- High-Shear (High-Energy)
- Plastic Bag
It is important to correlate the mass density of the granulation with the working capacity of the blender. Vibrations during tablet compression can, for example, cause segregation of the granulation in the feed bowl.
FILL WEIGHTS
However, the total costs of formulation should not be calculated only on the basis of excipients. The rule of thumb in the selection of excipients remains - keep it simple and to a minimum.
FINAL PACKAGING
Formulation costs — Although excipients make only a small contribution to the overall formulation, the declining costs of active pharmaceutical ingredients make the selection of excipients based on cost an important consideration. The purpose of the selection of excipients should be clearly defined: the dosage form should pass into a solution form at a predetermined rate (not necessarily the fastest in all cases).
FINAL TESTING
FINES
GEOMETRIC DILUTION
GRANULATION/MIX ANALYSIS A critical step in the manufacture of an oral solid dosage
In validating a drying process, LOD levels are determined before, during, and after drying to demonstrate times and levels. As with processing variables, levels (specifications) are established in the development phase, with the validation phase used to confirm process suitability.
INGREDIENT WARNING
In general, one of the following methods is required in an individual monograph, depending on the nature of the article. When the product contains water of hydration, method I (titrimetric), method II (azeotropic) or method III (gravimetric) is used, as indicated in the individual monograph.
MANUFACTURING YIELDS The formulas provided here include scale as well as quan-
When drying in a bottle stopped by the lid under vacuum is directed to the individual monograph, use a bottle or tube equipped with a stopper that has a capillary with a diameter of 225 ± 25 mm, and maintain the heating chamber with a pressure of 5 mm or less mercury. At the end of the heating period, admit dry air into the heating chamber, remove the bottle and, with the capillary stopper still in place, allow it to cool in a desiccator before weighing. As a result, determination of water content is important to demonstrate compliance with pharmacopoeial standards.
MASTER FORMULA
When drying in a desiccator is specified, take special care to ensure that the desiccant is kept fully effective by frequent replacement.
MULTIPLE-ITEM ENTRIES
However, there are instances where drug particles may need to be coated before they are incorporated into formulations. It is done to mask taste, for example in chewable tablets, to improve flow in tablets containing a higher proportion of the active ingredient, to provide special release properties or to protect the gastrointestinal mucosa (as in the case of particle-coated iron tablets, for example). Most particle coating methods involve a fluidized bed system or coating on a nonpareil sphere.
PRESERVATIVES IN COMPRESSED SOLID DOSAGE FORMULATIONS
Solid particles, once mixed, tend to segregate due to differences in the shape, size and density (other variables are also important) of the particles that compose them. This separation process takes place during mixing, but also during the subsequent treatment of the finished mixture. One of the most common reasons for post-mixing segregation (after adding lubricants) is over-mixing.
SIFTING INGREDIENTS AND GRANULES
These compacts are then ground and cleaned to form a granulation of the desired particle size. Most compressed tablets consist of the active ingredient and a diluent (filler), binder, disintegrating agent and lubricant. Tablets are required to meet a weight change test where the active ingredient constitutes a major part of the tablet and where the weight control can be assumed to be an adequate control of the uniformity of the drug content.
4-Amino-1-hydroxybutylidene-1,1-bisphosphonic Acid Tablets (5 mg)
Aminophylline Tablets (100 mg)
Amiodarone Tablets (200 mg)
Amlodipine Besylate Tablets [9]
Amitriptyline Tablets (50 mg) [42]
Amoxicillin Trihydrate and Clavulanate Potassium Tablets (500 mg/125 mg)
Amoxicillin and Potassium Clavulanate Tablets (250 mg/62.5 mg)
Amphetamine Salts Tablets
Atenolol Tablets (50 mg/100 mg)
Add the magnesium stearate and the remainder of the starch through a 0.6 mm stainless steel screen and mix for 25 minutes. Compress in a suitable tablet machine using round punches - the weight of 10 tablets is 2.075 g for the 50 mg strength and 4.15 g for the 100 mg strength; hardness more than 5; dissolution time no more than 15 min.
Atorvastatin Tablets (10 mg/20 mg)
Azithromycin Tablets (250 mg)
Benzafibrate Tablets (200 mg)
Benazepril Hydrochloride Tablets
Betamethasone Tablets (0.50 mg)
BIRB 796 Tablets (100 mg)
Bisoprolol Fumarate and Hydrochlorothiazide Tablets
Bromazepam Tablets (3 mg)
Bromhexine Tablets (8 mg)
Bromocriptine Tablets
Buflomedil Hydrochloride Tablets (150 mg/300 mg)
Buflomedil Hydrochloride Tablets (600 mg)
Bupropion Hydrochloride Tablets
Buspirone Hydrochloride Tablets
Buspirone Hydrochloride Tablets, Controlled - Release (30 mg)
Captopril Tablets (25 mg)
Carbamazepine Tablets (200 mg)
Carbidopa and Levodopa Tablets
Carisoprodol Tablets
Carvedilol Tablets
Cefadroxil Dispersible Tablets (250 mg)
Cefdinir Tablets (300 mg)
Cefixime Tablets (400 mg)
Cefprozil Tablets (250 mg)
Celecoxib Tablets
Cephalexin Tablets
Cetirizine and Pseudoephedrine Delayed-Release Tablets (5 mg/120 mg)
Cetirizine Hydrochloride Tablets (10 mg)
Chlorcyclizine Hydrochloride Tablets (50 mg)
Chlordiazepoxide and Clinidium Bromide Tablets (5 mg/2.5 mg)
Chlordiazepoxide Tablets (10 mg)
Chloroquine Tablets (250 mg)
Choline Theophyllinate Tablets (100 mg)
Chymotrypsine Tablets (25 mg)
Cilazapril Tablets (2.5 mg)
Cimetidine Tablets (200 mg)
Ciprofloxacin Tablets (500 mg)
Ciprofloxacin Tablets (750 mg)
Cisapride Tablets (5 mg)
Citalopram Hydrobromide Tablets
Clarithromycin Tablets (250 mg/500 mg)
Clenbuterol Tablets (20 mcg)
Clindamycin Tablets (20 mg)
Clobazam Tablets (10 mg)
Clomifen Citrate Tablets (50 mg)
Clomipramine Hydrochloride Tablets, Effervescent (300 mg)
Clomipramine Hydrochloride Tablets, Buccal (10 mg)
Clonazepam Tablets (1 mg/2 mg)
Clopidogrel Bisulfate Tablets (75 mg)
Conjugated Estrogens (0.3–2.50 mg)
Conjugated Estrogens and Medroxyprogesterone Tablets
Coumadin Tablets
Cyclobenzaprine Hydrochloride Tablets (10 mg) [64]
Cyproheptadine Tablets (4 mg)
Dapsone Tablets (50 mg)
Desloratidine Tablets (5 mg)
Desogestrel and Ethinyl Estradiol Tablets (0.15 mg/0.03 mg)
Diclofenac Sodium Tablets (25 mg)
Diclofenac Sodium Tablets (50 mg)
Diclofenac Sodium Tablets (100 mg)
Didanosine Tablets (50 mg)
Diethylcarbamazine Tablets (100 mg)
Difenoxin and Atropine Tablets (0.5 mg/0.025 mg)
Diltiazem Hydrochloride Tablets (60 mg)
Diltiazem Tablets 60 mg [95]
Diphenoxylate Hydrochloride and Atropine Sulfate Tablets (2.5 mg/0.025 mg)
Divalproate Sodium Tablets (125 mg) [121]
Feed coarse granules through either a 1.18 mm or 1.40 mm orifice screen mounted on an oscillating granulator. The lubrication stage should be carried out at no more than 40% relative humidity and at a maximum of 30°C. Compression steps must be performed at a maximum of 40% relative humidity and at a maximum of 26.5°C.
Divalproex Sodium Tablets (400 mg)
Pass the dried granulate through a 1.18 mm or 1.40 mm aperture screen fitted to a shaker granulator, or sweep the dry granules onto a 1.4 mm aperture screen fitted to a suitable sieve shaker. Add the silicon dioxide (Item 7) through a 1.7 mm aperture screen to the blender, followed by the balance of granule from Granulation Step 1d.
Doxycycline Hydrochloride Tablets (100 mg) [91]
Enalapril Maleate Tablets (10 mg)
Enoxacin Tablets (400 mg)
Erythromycin Ethylsuccinate Tablets (400 mg)
Erythromycin Particle-Coated Tablets (150 mg)
Erythromycin Tablets (100 mg)
Erythromycin Tablets (500 mg)
Pre-mix Amberlite with a small portion of the pellet and the mixture with about half of the bulk pellet for 5 min.
Estazolam Tablets (1 mg)
Estazolam Tablets (2 mg)
Ethambutol Tablets (400 mg)
Ethambutol Tablets (800 mg)
Etophylline and Theophylline Tablets (100 mg/22 mg)
Famciclovir Tablets (125 mg/250 mg)